Escient Pharmaceuticals IPO

Escient Pharmaceuticals is a biotech company specializing in the treatment of neurosensory-inflammatory disorders. Escient’s therapeutic programs apply state-of-the-art chemistries and biological understanding for its highly differentiated treatments using a novel class of cellular receptors called Mass-related G protein-coupled receptors (MRGPRS) that can detect and target a broad range of neuro-diseases.

Register for Details

For more details on financing and valuation for Escient Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Escient Pharmaceuticals

Forge green plus iconForge green minus icon

What is Escient Pharmaceuticals's funding to date?

Escient Pharmaceuticals has raised $243.51MM to date.
Forge green plus iconForge green minus icon

When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2015.

Who are Escient Pharmaceuticals's major investors?

Cowen Group
Perceptive Advisors
Redmile Group
Sanofi Genzyme BioVentures
Osage Partners
The Column Group
Altitude Life Science Ventures
NEA

Escient Pharmaceuticals funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
11/28/2022

Series C

$120MM raised $XXX.XX $XXX.XX
9/14/2020

Series B

$82.96MM raised $XXX.XX $XXX.XX
5/9/2018

Series A

$40.55MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jul 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.